```html

Hair Loss (Alopecia) – A Comprehensive Medical Guide

Overview

Hair loss, medically known as alopecia, refers to the partial or complete loss of hair from the scalp or other body areas. While a small amount of daily shedding (50‑100 hairs) is normal, noticeable thinning or bald patches may signal an underlying condition.

Who it affects: Alopecia can affect anyone, but patterns differ by age, sex, and ethnicity. Approximately 80 million Americans experience some form of hair loss in their lifetime, and up to 50 % of men and 40 % of women will notice significant thinning by age 50 – National Alopecia Areata Foundation, 2023.

Prevalence varies by type:

• Androgenetic alopecia (pattern baldness): 30 % of men and 25 % of women before age 30; >70 % of men by age 80.
• Alopecia areata (patchy autoimmune loss): ~2 % of the population worldwide.
• Scarring alopecia (cicatricial): much rarer, estimated <0.1 %.

Symptoms

Symptoms differ by alopecia type, but common manifestations include:

• Gradual thinning on top of the scalp – typical of androgenetic alopecia.
• Round or oval bald patches – classic for alopecia areata.
• Sudden, extensive shedding (telogen effluvium) after illness, surgery, or severe stress.
• Red, inflamed, or scaly patches that may lead to permanent scarring (cicatricial alopecia).
• Hair that breaks easily or appears “stubbly.”
• Changes in nail texture (pitting, ridging) – seen in some autoimmune forms.
• Associated symptoms: itching, burning, or pain on the scalp; in some cases, systemic signs such as fatigue or joint pain (especially with lupus-related alopecia).

Each symptom’s duration can range from weeks (telogen effluvium) to lifelong (genetic pattern baldness).

Causes and Risk Factors

Hair growth follows a 3‑phase cycle: anagen (growth), catagen (transition), and telogen (rest). Disruption of this cycle leads to hair loss.

Common Causes

• Genetic and Hormonal Factors – Androgenetic alopecia results from androgen sensitivity in genetically predisposed follicles.
• Autoimmune Activity – In alopecia areata, T‑cells attack hair follicles, causing sudden patchy loss.
• Physical or Emotional Stress – Triggers telogen effluvium; up to 40 % of cases follow a major stressor.
• Nutrient Deficiencies – Iron, zinc, biotin, and vitamin D deficiencies can impair keratin production.
• Medical Conditions – Thyroid disease, lupus, polycystic ovary syndrome (PCOS), and severe infections.
• Medications – Chemotherapy, anticoagulants, retinoids, beta‑blockers, and some antidepressants.
• Scalp Disorders – Fungal infections (tinea capitis), seborrheic dermatitis, or psoriasis.
• Trauma – Physical injury or hair‑pulling disorders (trichotillomania).

Risk Factors

• Family history of baldness (first‑degree relatives).
• Male sex (higher androgen levels) – however, women experience broader thinning.
• Age – risk increases with each decade after puberty.
• Ethnicity – higher prevalence of androgenetic baldness in Caucasians, lower in Asians.
• Chronic illnesses (e.g., diabetes, autoimmune diseases).
• Unbalanced diet or rapid weight loss.
• Smoking and excessive alcohol use – linked to vascular changes affecting follicles.

Diagnosis

Accurate diagnosis combines history, physical examination, and targeted testing.

Clinical Evaluation

1. Medical History – Onset, pattern, recent illnesses, medication list, family history.
2. Scalp Examination – Uses dermatoscope to view follicular openings, perifollicular inflammation, and signs of scarring.

Diagnostic Tests

• Blood Tests – CBC, ferritin, thyroid‑stimulating hormone (TSH), vitamin D, hormonal panels (androgens, estrogen).
• Scalp Biopsy – 4‑mm punch biopsy (often 2‑site) to differentiate scarring vs non‑scarring alopecia.
• Pull Test – Gentle tug of ~60 hairs; >10 % shedding suggests active telogen effluvium.
• Hair‐shaft Analysis – Microscopic examination for breakage patterns or fungal infection.
• Autoimmune Panels – ANA, anti‑thyroid antibodies when alopecia areata or lupus suspected.

Treatment Options

Treatment is tailored to the alopecia type, severity, patient preferences, and any underlying cause.

Medications

• Minoxidil (2 % topical, 5 % foam) – FDA‑approved for both men and women; promotes anagen phase. Typical response in 3‑6 months. Side effects: scalp irritation, unwanted facial hair.
• Finasteride (1 mg oral) – 5‑α‑reductase inhibitor for men; reduces DHT. Not approved for women of child‑bearing potential. Side effects: sexual dysfunction, rare depression.
• Dutasteride (0.5 mg oral) – More potent than finasteride; off‑label use for resistant pattern baldness.
• Corticosteroids – Intralesional triamcinolone for alopecia areata patches; short oral bursts for extensive disease.
• Topical Immunotherapy – Diphenylcyclopropenone (DPCP) or squaric acid dibutylester (SADBE) to provoke a mild allergic reaction, promoting hair regrowth.
• JAK Inhibitors – Oral tofacitinib or ruxolitinib showing promise in alopecia areata (clinical trials, FDA‑review pending).
• Antifungal agents – Oral terbinafine or itraconazole for tinea capitis.

Procedural Options

• Platelet‑Rich Plasma (PRP) – Autologous blood concentrate injected into scalp; evidence supports modest benefit in androgenetic alopecia.
• Low‑Level Laser Therapy (LLLT) – FDA‑cleared devices (comb, helmet) that may increase cellular metabolism.
• Hair Transplant Surgery – Follicular unit extraction (FUE) or transplantation (FUT) for permanent restoration in suitable candidates.
• Scalp Micropigmentation – Cosmetic tattooing to simulate density; useful when medical therapy fails.

Lifestyle and Supportive Measures

• Balanced diet rich in protein, iron, zinc, omega‑3 fatty acids, and vitamins A, C, D, E.
• Stress‑reduction techniques: mindfulness, yoga, therapy.
• Avoid harsh hair practices – tight braids, heat styling, chemical relaxers.
• Gentle cleansing with sulfate‑free shampoos; consider anti‑inflammatory scalp treatments (e.g., ketoconazole 2 % shampoo).
• Use of soft, breathable head coverings; consider wigs or hairpieces for cosmetic confidence.

Living with Hair Loss (Alopecia)

Hair loss can impact self‑image and emotional wellbeing. Practical strategies help maintain quality of life.

Daily Management Tips

• Scalp Care: Keep scalp clean but avoid over‑washing; pat dry gently.
• Protective Styling: Loose hairstyles, silk pillowcases, and avoiding excessive tension.
• Camouflage Options: Wigs, scarves, turbans, and hair fibers (e.g., keratin powders) can boost confidence.
• Regular Follow‑up: Monitor hair‑growth response every 3‑6 months; adjust therapy as needed.
• Psychological Support: Join support groups (Alopecia Areata Foundation, local meet‑ups) or seek counseling if anxiety or depression develops.
• Sun Protection: Scalp may be exposed after thinning; wear hats or SPF‑containing sprays.

Prevention

While genetic forms cannot be fully prevented, risk reduction for other types is possible.

• Maintain adequate iron ( ferritin > 70 ng/mL) and vitamin D levels; annual bloodwork for at‑risk individuals.
• Manage chronic conditions (thyroid disease, diabetes) promptly.
• Limit exposure to known hair‑damaging chemicals; choose gentle, paraben‑free products.
• Adopt a heart‑healthy lifestyle (regular exercise, balanced diet) to improve scalp circulation.
• Avoid extreme dieting; aim for gradual weight loss (<1 kg/week) if needed.
• Address stress early; consider therapy or relaxation programs for high‑stress occupations.

Complications

If left untreated, certain forms of alopecia can lead to:

• Permanent Scarring: Cicatricial alopecia destroys follicles, resulting in irreversible baldness.
• Psychosocial Distress: Increased rates of anxiety, depression, and social withdrawal (studies show up to 30 % of patients report clinically significant depression). Source: JAMA Dermatology, 2022.
• Sunburn or Skin Cancer Risk: Thinner scalp skin is more vulnerable to UV injury.
• Secondary Infections: Scratching or compromised scalp barrier can predispose to fungal or bacterial infections.

When to Seek Emergency Care

References

• Mayo Clinic. “Hair loss.” Updated 2023. https://www.mayoclinic.org
• American Academy of Dermatology. “Alopecia Areata Clinical Guidelines.” 2022.
• National Alopecia Areata Foundation. “Statistics & Facts.” 2023.
• Centers for Disease Control and Prevention. “Telogen Effluvium.” 2022.
• NIH – National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Androgenetic Alopecia.” 2021.
• JAMA Dermatology. “Psychological Impact of Alopecia: A Systematic Review.” 2022.
• Cleveland Clinic. “Hair Transplant Overview.” 2023.
• World Health Organization. “Guidelines for Diagnosis and Management of Scarring Alopecia.” 2021.

```